pharma

Zydus Lifesciences

ZYDUSLIFE · Nifty 50

1,061.4

Price 2026-06-17

BROAD EXPANSION73% confidence

At a Glance

Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: BROAD EXPANSION (73%).
Fundamental Score70/100 (STRONG). 1 positive flags, 5 concerns.
Historical Context170 similar technical setups. Average outcome: -7.9% decline. 0% positive.

Fundamental

70/100

STRONG

Trust

95/100

Verification

Coverage

44/100

LIMITED

Quick Take

Zydus Lifesciences scores 70/100 on fundamentals (strong). Zydus Lifesciences: BROAD EXPANSION regime.

Fundamental Score: 70/100 · STRONG · 2 signals detected

DuPont Analysis

ROE 18.3% broken into three drivers. Each shows how efficiently the company generates returns.

ROE18.3%=
18.4%Net Margin
×
0.5xTurnover
×
1.9xLeverage

ROE of 18.27% is moderate margin-driven and stable. Net margin of 18.4% × asset turnover of 0.51x × leverage of 1.9x.

What This Means

Net margin of 18.4% means the company keeps ₹18.4 as profit for every ₹100 of revenue. This is a healthy margin. Asset turnover of 0.51x means the company efficiently uses its assets to generate revenue. Leverage of 1.9x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.

Margin Structure

Gross

72.9%

Operating

26.0%

Net

18.4%

improving

Gross margin 72.9% → operating margin 26.0% → net margin 18.4%. Margins are IMPROVING. Strong pricing power with stable gross margins suggests the improvement is from operating leverage — sustainable.

Financial Health

Earnings Quality

WEAK

Cash flow only covers 0.4x of net income — earnings quality is WEAK. Profit may not be converting to cash. Check receivables and inventory.

Debt Sustainability

COMFORTABLE

Interest covered 16.9x — very comfortable. Debt service is not a concern. Debt/EBITDA at 1.5x is low — balance sheet has capacity.

Free Cash Flow

MODERATE

FCF margin negative at -2.1% — spending more than earning. Check capex cycle.

Peer Comparison

Zydus Lifesciences is compared against 10 peers in the pharma sector.

Key Watchpoints

🟢

Breaks above ₹1114 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹1008 (-5%)

Further downside risk

🟢

Pharma sector entering leadership

Sector rotation signal

Detected Patterns

➡️ Leverage Slowly Rising: Debt growing faster (288.9%) than equity (13.2%)
⚠️ Low Earnings Quality: Cash flow only 0.4x earnings — weak cash conversion

Risk Flags

🔴 2 Critical⚠️ 3 Warning1 Positive6 total flags
🔴Cash covers only 5% of current liabilities
Balance Sheet

Liquidity squeeze. Company may struggle to meet short-term obligations without refinancing.

🔴Operating cash flow significantly below net income
Cash Flow

OCF is only 0.4x net income. Profit not converting to cash — aggressive accounting possible.

⚠️Special charges present in income statement
Earnings Quality

Special charges of ₹517K Cr. May indicate restructuring, impairment, or one-time costs.

⚠️69% of debt is short-term
Balance Sheet

High refinancing risk. Company needs to roll over debt frequently. Vulnerable to credit market freezes.

⚠️Working capital changes are 124% of operating cash flow
Cash Flow

Working capital is consuming significant cash. Operational efficiency declining.

High promoter holding: 75%
Governance

Strong insider alignment. Promoters have significant skin in the game.

🔴 2 CRITICAL flags — significant concerns. Investigate before investing.

Data Quality

95/100All ratios self-computed from verified sources. 🟢 5 years of financial data — sufficient for trend analysis

News Correlation

margin pressure (4)management outlook (4)
⚠️ Our margin analysis (improving) contradicts news reports of margin pressure — investigate

50 articles scanned for fundamental themes

Facts

P/E Ratio
22.0UNAVAILABLE
P/B Ratio
4.4HIGH
Market Cap
₹11115866.4L CrHIGH
From 52W High
95% of high
Sector Peers
10
Zydus Lifesciences Stock Analysis, Valuation, Fundamentals & Intelligence | FynSight